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Abstract Aim Chemotherapy with indisulam causes myelosuppression. This study
aimed to evaluate the influence of patient-related covariates on pharmacokinetics
and pharmacodynamics, to identify patients at risk for severe myelosuppression and
to develop a dosing algorithm for treatment optimization. Methods Pharmacokinetic
and pharmacodynamic data of 412 patients were available. Non-linear mixed effects
modeling was used to determine the relative risk of dose-limiting myelosuppression
for various covariates (demographics, physical condition, prior treatment, comedi-
cation, CYP2C genotype and biochemistry). Results Body surface area (BSA), race
and CYP2C genotype had a significant impact on indisulam elimination
(P \ 0.001). Low BSA, Japanese race, variant CYP2C genotype, low baseline
neutrophil and thrombocyte counts and female sex were clinically relevant risk
factors of dose-limiting myelosuppression (RR [ 1.1). A dosing strategy was
developed to optimize treatment for patient subgroups. Conclusions This study has
identified covariates related to an increased risk of myelosuppression after indisu-
lam therapy. Dose individualization may contribute to treatment optimization.
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Introduction
Indisulam is an investigational anticancer agent that has been tested in multiple
single agent phase I and II studies. Myelosuppression was the dose limiting toxicity
(DLT) in dose escalation studies. Based upon the phase I program, an intravenous
1-h infusion of 700 mg/m2 was considered safe and was recommended for further
clinical evaluation [1].
Even though a dose of 700 mg/m2 was well tolerated by most patients, severe
hematological toxicity occurred in a subpopulation of patients [2–7]. Both
neutropenia and thrombocytopenia were frequently observed. Therapy with
indisulam was mainly limited by the occurrence of CTC (Common Toxicity
Criteria [8]) grade 4 neutropenia, causing an increased risk of severe or even life-
threatening infections [2–7].
The severity of haematological toxicity after treatment with indisulam showed
wide interpatient variability. We hypothesized that patient-related covariates may
explain interindividual differences in the severity of haematological toxicity.
Identification of relevant patient-related covariates and subsequent dose individu-
alization may reduce differences in indisulam-induced myelosuppression between
patients.
A clear relationship between indisulam pharmacokinetics and its haematological
toxicity was previously demonstrated by our group [9]. Consequently, differences in
indisulam-induced myelosuppression are partly caused by pharmacokinetic vari-
ability. In order to minimize pharmacokinetic variability, the dose of indisulam is
calculated based on body surface area (BSA). The benefit of BSA-guided dosing
was confirmed in a previous population pharmacokinetic study [10]. In addition, we
demonstrated that differences in indisulam pharmacokinetics were partly caused by
polymorphisms of CYP2C enzymes [11]. Genetic information may therefore also be
used for dose individualisation of indisulam. In the current analysis over the
complete data, we evaluated the impact of a large selection of patient-related factors
(demographics, physical condition, prior treatment, concomitant medication,
CYP2C genotype and biochemistry) on the pharmacokinetic profile of indisulam.
Differences in indisulam-induced myelosuppression may not only be caused by
pharmacokinetic variability. Pharmacodynamic variability may also play a major
role. Kloft et al. identified several patient-related covariates as risk factors for
neutropenia after treatment with taxanes or topoisomerase inhibitors [12]. For
indisulam, the impact of patient-related factors on the susceptibility of drug-induced
myelosuppression was investigated in this analysis.
Treatment with indisulam can be optimized by a priori identification of patients
at risk of severe myelosuppression. Subsequent dose individualization may (1)
prevent unnecessarily high risks of haematological DLT for more susceptible
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patients and (2) allow treatment with relatively high doses of indisulam for
patients who are less susceptible for haematological toxicity, which may be
beneficial for treatment efficacy. The aims of this study were (1) to investigate the
impact of patient-related covariates on pharmacokinetic and pharmacodynamic
parameters related to indisulam-induced hematological toxicity, (2) to identify
patients at risk of developing severe myelosuppression and (3) to develop an




Data from 7 phase I studies and 6 phase II studies were used (Table 1). Study
protocols were approved by the Medical Ethical Committees and all patients gave
written informed consent. Indisulam was administered in various schedules
(Table 1). Indisulam concentrations were measured in plasma, red blood cells
(RBC) and plasma ultrafiltrate. High-performance liquid chromatography methods
with UV detection were used for quantification of indisulam [10, 13]. The assays
were validated for the concentration range 0.02–50 mg/l. Assay accuracy and
precision were acceptable (\18.8%). Absolute neutrophil counts and thrombocyte
counts were determined twice weekly during the entire treatment course. All
treatment cycles that were monitored for pharmacokinetics and pharmacodynamics
were included in the current analysis.
Data analysis
All analyses were performed using NONMEM software (version V, double
precision, level 1.1) (Globomax LLC, Hanover, USA) [14]. The First-Order
Conditional Estimation (FOCE) method of NONMEM with interaction (INTER)
between the interindividual and residual random effects was the method of choice,
but this resulted in unacceptably long run times (multiple weeks). Therefore, the
First-Order (FO) method was used to fit logarithmically transformed concentration
time data (both drug concentrations and blood cell concentrations, see Eq. 5).
Discrimination between hierarchical models was based on the objective function
value (OFV) of NONMEM using the likelihood ratio test [14].
Pharmacokinetic and pharmacodynamic data were analyzed sequentially. The
pharmacodynamic parameters were estimated conditional on the previously
estimated population pharmacokinetic parameters and the pharmacokinetic data.
This method has been described in detail by Zhang et al. [15].
The final pharmacokinetic and pharmacodynamic model was used in simulation
studies to assess the relative risk of haematological DLT for various patient-
related covariates and to develop an algorithm for dose individualization (see
below).
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Basic pharmacokinetic and pharmacodynamic model
Semi-physiological models of indisulam pharmacokinetics and its hematological
toxicity have been developed [9, 16]. This pharmacokinetic model consisted of four
semi-physiological compartments: plasma (PL), RBC, interstitial fluid (IF) and
tissue (TIS) (Fig. 1). Indisulam was saturably bound to plasma proteins in plasma
and in IF (Bmax PL, KD PL, Bmax IF, KD IF), to carbonic anhydrase in RBC
(Bmax RBC, KD RBC) and to tissue components (Bmax TIS, KD TIS). In addition,
indisulam was non-specifically bound to RBC and tissue components (NRBC, NTIS).
Distribution between plasma and RBC was described by the intercompartmental
clearance QPL-RBC. The data did not contain sufficient information in order to
precisely estimate the intercompartmental clearance between plasma and IF.
Instead, the distribution between plasma and IF could be well described by an
instantaneous equilibrium. Drug elimination was described by two parallel
Table 1 Overview of all studies included in the covariate analysis
Study Phase Number of
patientsa






1 I 40 Solid tumours 1-h infusion, day 1 15 50–1,000 [1]
2 I 35 Solid tumours 1-h infusion, days 1–5 30 10–200 [25]
3 I 46 Solid tumours 1-h infusion, days 1, 8,
15 and 22, every
6 weeks
31 40–500 [26]
4 I 29 Solid tumours Continuous 120-h inf. 18 6–200 [27]
5d I 21 Solid tumours 1- or 2-h infusion 33 400–900 [13]
6 II 49 Colorectal cancer 1-h infusion, day 1 or
1-h infusion, days 1–5
11 700 [2]
7 II 44 Non-small cell
lung cancer
1-h infusion, day 1 or
1-h infusion, days 1–5
9 700 [3]
8 II 15 Head and neck
squamous cell
carcinoma
1-h infusion, day 1 10 700 [4]
9 II 25 Breast cancer 1-h infusion, day 1 7 700 [5]
10 II 28 Melanoma 1-h infusion, day 1 6 700 [6]
11 II 30 Renal cell cancer 1-h infusion, day 1 14 700 [7]
12 I 34 Colorectal cancer 1-h infusion, day 1
? capecitabine
18 350–800 [28]
13 I 16 Solid tumours 1-h infusion, day 1
? carboplatin
14 350–600 [29]
a Number of patients of whom pharmacokinetic and haematological data were available
b Indisulam was administered as mono-therapy every 3 weeks, unless indicated otherwise
c Average number of indisulam PK samples per pharmacokinetically evaluable patient
d Indisulam concentrations were measured in plasma, red blood cells and plasma ultrafiltrate in study 5.
In all other studies, indisulam concentrations were measured in plasma only
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pathways: a linear elimination pathway (CL) and a saturable Michaelis Menten
pathway (Vmax, Km).
The volumes of blood (calculated from gender and body surface area), RBC and
plasma (calculated from the blood volume and hematocrit) and IF (calculated from
body weight) were based on relationships that were supported by previous
publications [17, 18]. As indisulam was saturably bound to albumin, the maximal
binding capacity of indisulam in plasma and in IF was related to the albumin level.
The albumin level in IF was assumed to be 50% of the plasma albumin level [16].
The basic pharmacokinetic model of indisulam included these physiological-based
covariate relationships, but was free of any empirically determined covariate
relationships.
The basic pharmacokinetic model of indisulam also comprised an interaction
model of a pharmacokinetic drug–drug interaction with capecitabine. Indisulam
Fig. 1 Graphical representation of the pharmacokinetic and pharmacodynamic model of indisulam.
The dashed arrow corresponds to the myelosuppressive effect. Bmax: maximal specific binding capacity;
KD: equilibrium dissociation constant; N: non-specific binding constant; Q: intercompartmental
clearance; CL: clearance; Vmax: Michaelis Menten maximal elimination rate; Km: Michaelis Menten
constant; kprol: proliferation rate constant of progenitor blood cells; ktr: transition rate constant
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elimination was reduced by concomitant treatment with capecitabine. A metabolite
of capecitabine probably inhibits the synthesis of active CYP2C9 enzyme. An
interaction model was previously developed to describe the effect of capecitabine on
indisulam pharmacokinetics [19]. Briefly, an enzyme turnover model of five
sequential transit compartments was used to account for the drug–drug interaction
between indisulam and capecitabine for patients who were included in study 12. The
input into the enzyme turnover model was blocked during treatment with
capecitabine, which resulted in a reduction of the amount a active enzyme and
a consequent reduction of the saturable elimination rate of indisulam. The mean
transit time of the enzyme (MTTenzyme) was estimated [19].
A model of haematological toxicity was used to describe the time profiles of
neutrophils and thrombocytes. This model comprised a progenitor compartment of
proliferating blood cells, three transit compartments representing maturation chain
in the bone marrow and a compartment corresponding to the central circulation
(Fig. 1). The first-order rate constant for the transition between the transit
compartments is represented by ktr. The proliferation rate constant kprol was equal
to ktr in this model. A feedback mechanism was included, which represents the
effect of the release of endogenous growth factors as a response to the decrease of
cells in the systemic circulation. This mechanism influences the proliferation rate
and was incorporated in the model according to a power function of the ratio
between the cell count at baseline (C0) and the cell count at time t (Ct), according to
(C0/Ct)
c, where c is the estimated parameter of the feedback mechanism. This model
was linked to the pharmacokinetic model by a linear function (slope x Cindisulam)
that corresponded to the inhibition of cell proliferation by indisulam [9].
The previously published pharmacokinetic and pharmacodynamic models have
been developed using data from five phase I studies. In the current analysis, data
from eight additional studies were available. Therefore, the basic model could be
further developed prior to the covariate analysis. The structural pharmacokinetic
model as presented in Fig. 1 was re-evaluated. For the link function between
Cindisulam and the inhibition of cell proliferation (slope 9 Cindisulam), the free
concentration of indisulam in plasma was used, as opposed to the total plasma
concentration. Baseline neutrophil and thrombocyte counts were estimated from the
last measurement that was performed prior to the first administration of study
treatment.
Covariate analysis
Potentially relevant covariates were tested to be related to pharmacokinetic and/or
pharmacodynamic parameters of indisulam. A pre-specified analysis plan was used.
Only covariate relationships that were considered plausible were evaluated
(Table 2). For instance, we investigated the effect of the concomitant use of
granulocyte colony-stimulating factor (G-CSF) on the turnover time of blood cells,
on the cytotoxic effect of indisulam and most importantly on the feedback
parameter gamma, which represented the effect of endogenous growth factors. Prior
treatment might have resulted in bone marrow damage and thus might be related to
pharmacodynamic parameters. Concomitant use of inductors and inhibitors of the
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Table 2 Patient-related covariates that were tested for their impact on the PK/PD parameter of interest
Covariate Observed values in




Ascites Yes 44 VISF, CL, Vmax
No 330
Missing 38
Liver metastates Yes 133 CL, Vmax
No 238
Missing 41
ECOG performance status [30]
(=W.H.O. score)
0 190 PK parametersa and









Sex Male 229 PK parametersa and
Female 183 PD parametersb
Age (years) Range 19–82 PK parametersa and
Median 57 PD parametersb
Weight (kg) Range 41–145 PK parametersa
Median 69
Height (cm) Range 145–203 PK parametersa
Median 168
Body surface areac (m2) Range 1.33–2.44 PK parametersa
Median 1.78
Prior treatment





0 94 PD parametersb
1 or 2 209
3 or more 88
Missing 21
Prior platinum-based chemotherapy Yes 155 PD parametersb
No 231
Missing 26
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Table 2 continued
Covariate Observed values in




G-CSF Yes 9 PD parametersb
No 382
Missing 21
CYP2C inductorsf Yes 60 CL, Vmax
No 331
Missing 21













ALAT (U/l) Rangee 5–114 CL, Vmax
Median 19
Missing n = 31
Bilirubin (umol/l) Rangee 3.0–21 CL, Vmax
Median 8.0
Missing n = 30
Creatinine clearanced (ml/min) Rangee 45–155 CL, Vmax
Median 82
Missing n = 30
a PK parameters describing tissue distribution and drug elimination (QIF-TIS, NTIS, Bmax TIS, KD TIS,
Vmax, CL)
b PD parameters for neutrophils (NEU) and platelets (PLT), describing the mean transit time (MTTNEU,
MTTPLT), the impact of the positive feedback mechanism (gammaNEU, gammaPLT) and the cytotoxic
potency of indisulam (slopeNEU, slopePLT)
c Calculated from weight and height according to the Dubois–Dubois formula
d Calculated from sex, age, weight and serum creatinine according to the Cockcroft–Gault formula
e Range was reported as the 2.5–97.5 percentiles in order to exclude outliers
f Cytochrome P450 inductors and inhibitors were selected according to the Cytochrome P450 Drug-
Interaction Table from the Indiana University Department of Medicine. [http://medicine.iupui.edu/
flockhart/table.htm]
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cytochrome P450 2C enzymes and genetic variation of these enzymes might have
impact on the biotransformation of indisulam. Demographic covariates were related
to pharmacokinetic and pharmacodynamic parameters.
Selection of covariate relationships was based on statistical significance using the
likelihood ratio test. Covariate effects that were significant at a level of 0.05 in
univariate analysis were included into an intermediate model. The significance level
during backward elimination was more strict (P \ 0.001).
For covariate effects included in the model after backward elimination (pre-final
model), the contribution of each patient to the difference in OFV (between the pre-
final model with and without the covariate effect of interest) was calculated. These
individual differences in the OFVs were used as a tool to identify patients having a
large impact on the difference in OFV for the covariate effect of interest [20].
Covariate relationships that were driven by single or very few patients were
excluded from the pre-final model, which resulted in the final model.
Dichotomous (DI), ordinal (OR) and continuous (CO) variables were tested and
the respective covariate relationships were defined according to Eqs. 1, 2 and 3,
respectively. Dichotomous variables were either 0 or 1. Ppop was the typical
population value of parameter P and Pg corresponded to the typical value of P for
the gth group of individuals with identical covariate values. The value of the
covariate factor CF determined how strong P was influenced by the covariate.
Pg ¼ Ppop  1 þ CFð ÞDIg ð1Þ
Pg ¼ Ppop  1 þ CF  ORg
  ð2Þ





Patients with missing categorical covariates were considered as an additional
subgroup with their own typical parameter value. For instance, during evaluation of
the covariate ‘liver metastates’, three subgroups were identified (liver metastases:
yes, liver metastases: no, liver metastases: unknown/missing), which resulted in a
model with two extra typical effects. Missing continuous covariates were estimated
from log-normal distributions. The geometric mean and variance of missing
covariates were assumed to be identical to the geometric mean and variance of
observed continuous covariate values.
Random effect models
Variances of random differences between individuals in each pharmacokinetic
parameter were estimated using exponential models (Eq. 4). In this equation, Pi
represents the value of parameter P for the ith individual, Pg is the typical
group value and g is the interindividual random effect with mean 0 and
variance x2.
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Pi ¼ Pg  egi ð4Þ
Differences between observed and individual predicted concentrations (both drug
concentrations and blood cell concentrations), resulting from measurement error and
model misspecification, were also regarded as random effects and were modeled as
exponential errors using:
ln Cobsij
  ¼ ln Cpredij
 þ eij ð5Þ
where e is the residual error with mean 0 and variance r2, representing the
difference between the natural logarithm of the jth observed concentration in the ith
individual (ln(Cobs ij)) and its respective prediction (ln(Cpred ij)). The variances of
the residual errors of baseline neutrophil and thrombocyte counts and the variances
of the residual errors of post-treatment neutrophil and thrombocyte counts were
assumed to be identical, respectively.
Clinical relevance
Statistically significant covariates were tested for clinical relevance. The risk of
haematological DLT, defined as neutropenia CTC grade 4 during [7 days and/or
thrombocytopenia CTC grade 4, was used to assess clinical relevance. Groups of
patients were simulated to determine the relative risk of haematological DLT for
each covariate after administration of 700 mg/m2 indisulam in a 1-h infusion. The
covariate in question was set to the 2.5 percentile (group 1), the 50 percentile (group
2) or the 97.5 percentile (group 3) of the observed covariate values. The other
covariates corresponded to the observed covariates in the study population. Each
observed combination (n = 412) was used 10 times in each simulated group.
Consequently, each group comprised 4,120 patients. The relative risks of group 1
and 3 were defined as the ratios between the frequencies of haematological DLT in
group 1 or 3, and the frequency of haematological DLT in group 2. A covariate
effect was considered clinically relevant if the relative risk of haematological DLT
after treatment with 700 mg/m2 indisulam was estimated to be less than 0.9 or more
than 1.1 for either group 1 or group 3.
For a group size of 4,120 patients, the complete 95% confidence interval of the
simulated relative risk was between 0.9 and 1.1 for covariates with no effect on
clinical outcome. For covariates that were related to a 20% change in the risk of
haematological DLT, the 95% confidence interval of the simulated relative risk was
completely below 0.9 or completely above 1.1. Therefore, this strategy guaranteed
exclusion of covariates with no effect on clinical outcome (confidence level[0.95)
and selection of covariates that were related to a 20% change in the risk of
haematological DLT (power [0.95).
In this simulation study, each patient-related covariate was individually assessed
for its relative risk of dose limiting myelosuppression. However, independent
evaluation of body size measures (i.e. weight WT, height HT, body surface area
BSA) would have resulted in simulation of subjects with impossible combinations
of covariate values, for instance high WT, high HT and low BSA. To prevent this,
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highly correlated body size measures evaluated simultaneously, which resulted in a
relative risk for small (WT = 42 kg and BSA = 1.42 m2) and large (WT = 109 kg
and BSA = 2.25 m2) body size.
Identification of patients at risk
The final model, including all covariates that were statistically significant, was
applied to identify patients at risk. In this part of the simulation study, the impact of
real-life combinations of covariates (e.g. female sex, Japanese race, small body size,
CYP2C19*1/*3 genotype) was assessed in contrast to an evaluation of single
covariate. To avoid bias caused by correlation between the various patient-related
covariates, only combinations of covariates that were observed in the study
population (n = 412) were taken into consideration. Using the observed combina-
tions of patient-related covariates, 412 groups of 1,000 patients were simulated to
receive 700 mg/m2 indisulam in a 1-h infusion. The overall absolute risk of
haematological DLT was defined as the proportion of patients who experienced
neutropenia CTC grade 4 during [7 days and/or thrombocytopenia CTC grade 4.
The group size of 1,000 patients guaranteed a small relative standard error of the
risk simulation (0.05 for a proportion of 0.3). The 412 combinations of covariates
were ranked according to the risk of haematological DLT. Covariate values of
patients 1–41 (top 10%) were compared to the covariate values of patients 372-412
(lower 10%) in order to verify which covariates were related to high or low risk of
haematological DLT. The relationships between each covariate and the risk of
haematological DLT were visualized in scatter plots.
Algorithm for dose individualization
A selection of clinically relevant covariates was included in the dosing algorithm.
The covariate values of each patient were used to define a score and an
individualized dose. Covariate values that were related to an increased risk of
haematological DLT required a dose reduction and covariate values that were
related to a reduced risk required a dose increment. In a step-wise process, various
possible algorithms for dose individualization were evaluated by the same method
that was used to identify patients at risk. Using the observed combinations of
patient-related covariates, 412 groups of 1,000 patients were simulated to receive an
individualized dose of indisulam in a 1-h infusion. Thus, each of the 412 observed
combinations was used to randomly draw 1,000 patients from the population PK-PD
model, the PK-PD profiles after indisulam treatment were simulated and haema-
tological toxicities were scored. In each step, correlations between the risk of
haematological DLT and the relevant covariates were assessed. If a correlation was
still present, the corresponding dose adjustment was increased in the next step. If the
direction of a correlation was inversed, the corresponding dose adjustment was
reduced in the next step. The algorithm for dose individualization resulting in (1) an
acceptable overall absolute risk of haematological DLT for oncology clinical
practice of 33% and (2) minimization of the correlation between each patient
characteristic and the risk of haematological DLT was finally selected.




Pharmacokinetic and hematological measurements were available from 412
patients. The 412 patients received a total of 1,263 treatment cycles (median:
2 cycles). Treatment duration varied from 1 day to 26 months. In total, 6,349
indisulam concentrations in plasma were measured in 594 treatment cycles. In
a subgroup of 21 patients, 308 concentrations of indisulam were determined in RBC
and 42 in plasma ultrafiltrate. 2,669 Absolute neutrophil counts and 2,762
thrombocyte counts were available from all patients. The data set was considerably
larger than the data set that was used for a previously published pharmacokinetic
analysis of indisulam [16].
Optimization of basic pharmacokinetic and pharmacodynamic model
The pharmacokinetic model was improved with the addition of an extra peripheral
compartment (DOFV = -760). The concentration of albumin in the extra
peripheral compartment was assumed to be the same as in IF. The intercompart-
mental clearance between the IF compartment and the extra peripheral compartment
was large (771 l/h). The volume of distribution was estimated at 19.3 l.
The relationship between indisulam pharmacokinetics and the inhibition of cell
proliferation was modeled by a linear function (slope 9 Cindisulam). The
likelihood of the model increased (DOFV= -8) when total plasma concentrations
were replaced with free plasma concentrations of indisulam, while the total
number of estimated parameters remained unchanged. The relationship between
indisulam pharmacokinetics and the inhibition of cell proliferation was also
included as an Emax model, but Emax and EC50 values could not be estimated
independently.
Sequential analysis of pharmacokinetic and pharmacodynamic data was justified
by the results since the empirical Bayesian estimates of the pharmacokinetic
parameters were very similar for the pharmacokinetic model and the pharmaco-
kinetic-pharmacodynamic model.
Patient-related covariates
Table 2 lists the frequencies and observed ranges of the patient-related covariates
that were evaluated in this covariate analysis. Data on physical condition,
demographics, prior treatment, concomitant medication and clinical chemistry
parameters could be retrieved for the majority of the patients. For each covariate,
Table 2 indicates the number of patients with an unknown value. Genotype data
were available for patients who participated in studies 5, 12 and 13 (Table 1).
Baseline neutrophil counts (median 5.3 9 109/l, missing n = 51) and baseline
thrombocyte counts (287 9 109/l, missing n = 42) were part of the basic models of
neutropenia and thrombocytopenia.
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Covariate selection for pharmacokinetic parameters
Out of 61 covariate relationships that were tested in univariate analyses, 28 were
statistically significant. Six covariate relationships remained after backward
elimination. The pharmacokinetic parameter estimates of the final model are listed
in Table 3. More details of the significant covariate relationships are presented in
Table 4.
Both the linear and the saturable elimination rates of indisulam were related to
measures of body size. The linear clearance (CL) of indisulam was significantly
related to body weight (CLg = CLpop[WT/69]CF, see Eq. 3). The covariate factor
CF was not significantly different from 0.75, which is in accordance with allometric
scaling [21]. Patients with a BSA of 2.1 m2 had a 22% larger Vmax than patients
with median BSA. The maximal elimination rate Vmax was reduced by 31% for
heterozygous CYP2C9*3 mutations and the linear clearance was reduced by 49%
for heterozygous *2 or *3 mutations in the gene encoding for CYP2C19. As
expected, the typical values of Vmax and the linear clearance for patients with
unknown genotype were between the values for wildtype patients and patients with
a variant genotype. Caucasian patients had a 61% larger Vmax than Japanese
patients. Body weight was inversely related to specific binding of indisulam in body
tissue.
In addition, ascites was borderline significantly related to the clearance of
indisulam. The impact of ascites on indisulam pharmacokinetics could be accounted
for by an increased distribution volume of indisulam for patients with ascites, but
the volume of the extra peripheral compartment was not different for patients with
and without ascites.
Covariate selection for pharmacodynamic parameters
Table 3 shows the pharmacodynamic parameter estimates of the final model and the
covariate relationships that were statistically significant are listed in Table 4. The
turnover time of neutrophils and thrombocytes was shorter for females than for
males. Prior chemotherapy was related to higher sensitivity of neutrophils to the
cytotoxic effect of indisulam.
Concomitant use of granulocyte colony stimulating factor (G-CSF) did not
significantly affect the feedback parameter gamma of neutrophils. Unexpectedly,
patients who were treated with G-CSF were significantly more susceptible to the
myelosuppressive effect of indisulam. This should not be interpreted as a causal
relationship, since it is very unlikely that treatment with G-CSF caused an increase
in haematological toxicity of indisulam. The observed relationship is rather due to
selection bias: patients who were susceptible for the haematological effects of
indisulam were more likely to be treated with G-CSF (see discussion). It was
concluded that the design of this study was not suitable to investigate the effect of
G-CSF on haematological toxicity. Hence, the impact of G-CSF treatment on
clinical outcome was not further investigated in simulation studies.
The statistical covariate analysis suggested that the cytotoxic potency of
indisulam for thrombocytes was reduced in older patients (DOFV = -17).
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Bmax PL Binding capacity PL protein (mg/l) [albumin]PL







NRBC Non-specific binding const.
RBC
91.8 8.5%
Bmax RBC Binding capacity RBC (mg/l) 57.9 27% 7.5%
KD RBC Dissociation constant RBC (mg/l) 0.00260 8.5%
Bmax IF Binding capacity IF (mg/l) Bmax PL
50%c
(fixed)
KD IF Dissociation constant IF (mg/l) 0.25
b
(fixed)
QIF-TIS Intercompartmental CL IF-TIS (l/h) 2,630 70% 11%
NTIS Non-specific binding const.
TIS
9.74 87% 80%
Bmax TIS Binding capacity TIS (mg/l) 5.79 61% 15%







Vmax Maximal elimination rate (mg/h) 4.30 52% 12%
Km Michaelis Menten constant (mg/l) 0.0013 18%
CL Plasma clearance (l/h) 132 18%
MTTenzyme Mean transit time enzyme
(capecitabine interaction)
(h) 195 31% 0.7%
Pharmacodynamic model




Slopeneu Cytotoxic potency for
neutrophils
(l/mg)a 16.4 87% NE
MTTplt Mean transit time platelets (h) 105 21% NE
Gammaplt Feedback parameter platelets 0.165 46% NE
Slopeplt Cytotoxic potency for platelets (l/mg)
a 10.7 120% NE





CPL total Total plasma conc. indisulam (%) 33
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However, the individual difference in the OFV was large for one patient
(DIOFV = -25) and very small for the other 411 patients. This demonstrated
that the effect of age on the inhibition of cell proliferation was driven by a single
patient and this relationship was not taken into account in further simulation studies.
Clinical relevance
The relative risk was larger than 1.1 for female patients (RR = 1.18) as well as for
patients from Japanese origin (RR = 1.19), with small body size (RR = 1.13 for
WT = 45 kg and BSA = 1.42 m2), with a variant CYP2C9 genotype (RR = 1.38
for homozygous CYP2C9*3 mutants) and with a variant CYP2C19 genotype
(RR = 2.34 for homozygous CYP2C19*2 or *3 mutants) (Table 4). Despite the fact
that a BSA-based dosing strategy was employed, body size had a moderate impact
on the risk of haematological DLT after a 700 mg/m2 dose (RR = 1.13 for
WT = 45 kg and BSA = 1.42 m2). Prior chemotherapy did not lead to a clinically
relevant increase in risk of toxicity (Table 4).
Identification of patients at risk
The overall absolute risk of haematological DLT at the first cycle of treatment with
700 mg/m2 indisulam was 0.32. Despite BSA-based dosing (700 mg/m2), the 10%
patients with the highest risk of dose limiting myelosuppression had a smaller body
size as compared to the 10% lowest risk patients (Fig. 2a, b). High risk patients also
had lower baseline blood cell counts (Fig. 2c, d). Moreover, the high risk group
comprised more female (34 vs. 12) and Japanese patients (14 vs. 0) than the low risk
group and more high risk patients had one or more CYP2C19 mutations (13 vs. 1).
The patient with the lowest risk of dose limiting haematological toxicity was a
Caucasian male patient with large body size (BSA = 2.23 m2, weight = 119 kg)
and a wildtype CYP2C genotype. The patient with the highest risk was a Japanese
female patient with small body size (BSA = 1.4 m2, weight = 47 kg) who was










CPL free Free plasma conc. indisulam (%) 38
CRBC Conc. indisulam in erythrocytes (%) 11
ANC Absolute neutrophil count (%) 37
TC Thrombocyte count (%) 27
NE not evaluated
a Based on free plasma concentrations of indisulam
b The equilibrium dissociation constant was determined in a previous non-dynamic analysis [31]
c The albumin concentration in interstitial fluid was assumed to be 50% of the plasma level [32]
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Algorithm for dose individualization
The clinically relevant patient-related covariates were considered for inclusion into
the dosing strategy. Baseline platelet and neutrophil counts were correlated and it
was therefore sufficient to only include the baseline neutrophil count into the dosing
algorithm. The correlation between the risk of haematological DLT and body size
measures was weaker after BSA-based dosing than after weight-based dosing.
Hence, BSA-based dosing was superior over weight-based dosing. Female and
Table 4 Statistically significant covariate relationships and their clinical relevance
Related
parameterg
Covariate effect Relative risk (RR) of dose limiting
haematological toxicity
Pharmacokinetic covariates
Body surface area (m2) Vmax (BSA/1.78)
1.20 BSA = 1.42/WT = 45 ? RR = 1.13
Racee Vmax (1 ? 0.613)
race Japanese ? RR = 1.19
WT (kg) CL (WT/69)0.75 WT = 45/BSA = 1.42 ? RR = 1.13
WT (kg) Bmax TIS (WT/69)
-0.621 WT = 45/BSA = 1.42 ? RR = 1.13
CYP2C9 *3 polymorphismd Vmax (1–0.309  MUT) Heterozygous ? RR = 1.15
homozygous ? RR = 1.38
CYP2C19 *2/*3
polymorphismd
CL (1–0.487  MUT) Heterozygous ? RR = 1.45
homozygous ? RR = 2.34
Pharmacodynamic covariates
Sexb MTTneu (1 ? 0.225)
sex Female ? RR = 1.18
G-CSFa MTTneu (1–0.263)
G-CSF Not evaluatedf
G-CSFa Slopeneu (1 ? 1.04)
G-CSF Not evaluatedf
Prior chemotherapy (PCc) Slopeneu (1 ? PC  0.0994) PC = 2 ? RR = 1.06
Sexb MTTplt (1 ? 0.214)
sex Female ? RR = 1.18
G-CSFa MTTplt (1 ? 0.438)
G-CSF Not evaluatedf
G-CSFa Gammaplt (1 ? 0.422)
G-CSF Not evaluatedf
G-CSFa Slopeplt (1 ? 2.57)
G-CSF Not evaluatedf
Age (years) Slopeplt (age/57)
-0.612 Not evaluatedf
a 0 = no; 1 = yes
b 0 = female; 1 = male
c no prior chemotherapy: PC = 0; one or two prior courses: PC = 1; three or more prior courses:
PC = 2
d MUT = number of mutated alleles (wildtype: MUT = 0; heterozygous: MUT = 1; homozygous:
MUT = 2)
e 0 = Japanese; 1 = Caucasian/Hispanic/Black
f low predictive value (see Results—Covariate selection for pharmacodynamic paremeters) and therefore
not further evaluated
g Vmax: maximal saturable elimination rate; CL: clearance; Bmax TIS: maximal binding capacity in tissue;
MTT: mean transit time of neutrophils (neu) and platelets (plt); slope: cytotoxic potency of indisulam;
gamma: feedback parameter representing the effect of endogenous growth factors
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Japanese patients required a dose reduction as well as patients with a mutant CYP2C
genotype. Table 5 shows the proposed algorithm for dose individualization of
indisulam. The proposed indisulam dose for Caucasian male patients with a wildtype
CYP2C genotype and a baseline neutrophil count between 4 9 109/l and 8 9 109/l
was 775 mg/m2. Patients with female sex, variant CYP2C genotype, Japanese race
and/or a baseline neutrophil count below 4 9 109/l required a reduced dose.
Conversely, a dose increment was indicated for patients with a baseline neutrophil
count above 8 9 109/l. In Table 5, two examples of the application of the dosing
algorithm are presented. A dose of 900 mg/m2 is recommended for a Caucasian
male patient with a wildtype genotype and a baseline neutrophil count of 9 9 109/l
and a dose of 375 mg/m2 is recommended for a Japanese female patient who is
homozygous for the CYP2C19*2 mutation. Correlations between risk factors and
the risk of severe myelosuppression resolved upon the application of this dosing
algorithm (Fig. 3). Figure 4 demonstrates that some patients required a reduced
dose of indisulam in order to enhance treatment safety. Conversely, around 50% of
the patients could be treated with a higher dose than the standard 700 mg/m2, which
may be beneficial for treatment efficacy.
Fig. 2 Box-and-whisker diagrams of covariates in the 10% highest and the10% lowest risk patients after
treatment with 700 mg/m2 indisulam administered in a 1-h infusion. Body surface area (a), weight (b),
baseline neutrophil count (c) and baseline thrombocyte count (d) were lower in the high risk group. The
boxes correspond to the interquartile range (IQR) Q25–Q75 and observations more than 1.5 * IQR below
Q25 or more than 1.5 * IQR above Q75 are indicated (O˜)
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The overall absolute risk of dose limiting myelosuppression was the same for the
original BSA-based dosing strategy (risk = 0.32) and the new dosing algorithm
(risk = 0.33). However, the distribution of the individual risk probability for DLT
was wider with BSA-based dosing as compared to the new dosing algorithm
(Fig. 5). In order to produce Fig. 5, the individual risk of dose limiting
myelosuppression was calculated for each of the 412 patients. Patients were ranked
from low to high risk, resulting in a patient ranking number (1-412). This number
was plotted against the risk of dose limiting haematological toxicity. The
distribution was narrowed and the risk of dose limiting myelosuppression was
partly equalized by the application of the new dosing algorithm. All patients had a
risk between 15% and 55% after application of the new dosing strategy, in contrast
to the BSA-based dosing where the risk was between 14% and 78%.
Discussion
In this study, we evaluated the impact of patient-related covariates on indisulam-
induced myelosuppression. Patients with low neutrophil counts and/or polymor-
phisms of the gene encoding for the CYP2C enzymes had an increased risk of
haematological DLT after treatment with indisulam. Additional risk factors were
Table 5 Algorithm for dose individualization of indisulam








Heterozygous CYP2C19*2 or *3 -6





\4 9 109/l -5
[8 9 109/l ?5 ?5
Total score ?5 -16
Individual dose (mg/m2) 775 ? total score25 900 375
a Example 1: application of the dosing algorithm for a Caucasian male patient with a wildtype genotype
and a baseline neutrophil count of 9 9 109/l
b Example 2: application of the dosing algorithm for a Japanese female patient with a *2/*2 genotype for
CYP2C19
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female sex and Japanese race. These risk factors were included into a dosing
algorithm for individualization of treatment with indisulam.
The baseline neutrophil count was identified as the most important characteristic
for dose individualization of indisulam. Neutrophil counts are determined as routine
clinical practice prior to chemotherapy. If these cell counts are below predefined
criteria, a dose delay may be indicated. This study shows that neutrophil counts can
not only be used to determine whether a patient’s condition allows treatment with
indisulam, but also to define which dose is required for treatment optimization.
In this study, it was assumed that patients are optimally treated by the highest
safe dose of indisulam. This assumption seems reasonable for the cell cycle
inhibitor indisulam, but future studies to further investigate the relationship between
drug exposure and antitumour effect are warranted.
The impact of CYP2C polymorphisms on the risk of myelosuppression was
previously investigated by our group. In this previous study, the CYP2C9*3
polymorphism was significantly related to a reduced maximal elimination rate
(Vmax) of indisulam [11]. Concurrent treatment with capecitabine was also related to
a reduction of Vmax [19]. In the current analysis over the complete data, the effect of
Fig. 3 Plots of the risk of severe myelosuppression versus baseline neutrophil counts a and CYP2C19
genotype c after treatment with 700 mg/m2 indisulam administered in a 1-h infusion. b and d show the
corresponding plots after application of the dosing algorithm
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Fig. 4 Distribution of individual indisulam doses for BSA-based dosing (a and c) and for the dosing
algorithm (b and d) calculated for each of the 412 patients in the study population, in mg/m2 (a and b)
and as an absolute dose after correction for body surface area (c and d)
Fig. 5 The distribution of the risk probability for the study population (n = 412) for flat dosing (),
BSA-based dosing ( ) and for the dosing algorithm (d). Patients were ranked from low risk (lower left)
to high risk (upper right). The application of the dosing algorithm resulted in a more uniform distribution
of the risk, which resulted in a steeper curve
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the CYP2C9*3 mutation was not statistically significant due to correlation of
CYP2C9 genotype and concomitant use of capecitabine in the study population.
High body weight was related to low maximal binding capacity of indisulam in
body tissue. Although the exact nature of specific and non-specific binding of
indisulam to tissue components is unknown, our results imply that the binding
capacity of fat tissue is lower than the binding capacity of lean body tissue. High body
weight was also related to high indisulam clearance. The  power law of allometric
scaling was successfully applied to include this effect into the covariate model [21].
The effect of G-CSF on neutropenia was previously demonstrated by Kloft et al.
[12]. For neutrophil counts, the feedback parameter gamma was increased in
patients who received G-CSF after chemotherapy. This effect was not demonstrated
in the current study. Conversely, the cytotoxic effect of indisulam was relatively
high in patients who were treated with G-CSF. This observation is most likely due
to selection bias: patients who were very sensitive to the cytotoxic effect of
indisulam were treated with G-CSF on medical indication.
In the previously published models of chemotherapy-induced neutropenia and
thrombocytopenia, the cytotoxic effect of anticancer drugs was related to total plasma
concentrations. In the current study, however, the cytotoxic effect of indisulam was
considered proportional to its free plasma concentrations. This consideration was in
accordance with the free-drug hypothesis, which suggests that only free drug in
plasma determines in vivo drug effects. This has been demonstrated for several drugs,
such as lidocaine and beta-receptor antagonists [22, 23]. For indisulam, the likelihood
of the myelosuppression model was increased indeed when free plasma concentra-
tions of indisulam were used instead of total plasma concentrations.
Special consideration was given to the problem of missing covariates in this
analysis. It was attempted to estimate missing covariates from a mixture model
(nominal data) and from log-normal distributions (continuous data). Unfortunately,
the mixture method resulted in unacceptably long run times. Therefore, an extra
typical parameter value was estimated for patient subgroups with missing covariates
in order to avoid bias.
Parameter estimates generally corresponded well to previously reported values
[9, 24] This indicates that the parameter estimates were largely independent of the
estimation method in NONMEM, which supports the adequacy of the FO method
for this analysis.
Patient-related covariates might not always have a large impact in univariate
analyses, but might become relevant in combination with other patient-related
covariates. Therefore, the evaluation of interaction terms of covariate effects was
considered. This resulted in model over-parameterization. Yet, we took co-linearity
between covariate effects into account by using only observed combinations of
patient-related covariates in the simulation studies.
A dosing algorithm was developed to promote safety and efficacy of treatment
with indisulam. A Japanese female patient with a CYP2C19*2/*2 genotype will
have an acceptable risk of dose limiting myelosuppression after treatment with
a reduced dose of 375 mg/m2 indisulam. A Caucasian male patient with a wildtype
genotype and a baseline neutrophil count of 9 9 109/l can be optimally treated with
a dose of 900 mg/m2.
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The proposed dosing algorithm is expected to result in a risk of haematological
DLT between 15% and 55% for all patients. Complete equalization of the risk of
haematological DLT would have required a much more complex dosing algorithm.
This is related to the highly non-linear pharmacokinetic profile of indisulam. The
proposed dosing algorithm was selected as the optimal algorithm, given that it
should be feasible for implementation in clinical practice.
In conclusion, this study has identified patient-related covariates related to an
increased risk of haematological adverse effects after therapy with indisulam. Dose
individualization based on these patient-related covariates might result in safer
treatment for high risk patients and more effective treatment with higher doses for
low risk patients. Dose individualization using the proposed algorithm may
contribute to optimization of treatment with indisulam.
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